drugset / Trial / NCT07010575

Patient Preference Study: Standard of Care Versus Once-daily Trientine Tetrahydrochloride

NCT07010575

Phase 2 Completed 10 enrolled Orphalan
NaSingle-groupOpen-labelTreatment

Summary

Decentralized study to assess patient reported treatment satisfaction comparing their current standard-of-care Wilson's Disease (WD) treatment with a new once-daily Trientine (TETA) 4HCl formulation.

Timeline

Start
2025-07-15
Primary completion
2025-12-18
Completion
2025-12-18

Drugs

EvaluationDrugModalityDoseRoute
Subject trientine Unknown 300 mg

Indications